Published in Cancer Cell on August 14, 2012
Therapy for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia | NCT00137111
Total Therapy Study XVI for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia | NCT00549848
Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia. N Engl J Med (2014) 5.37
Acute lymphoblastic leukaemia. Lancet (2013) 3.44
Pediatric acute lymphoblastic leukemia: where are we going and how do we get there? Blood (2012) 2.82
RAG-mediated recombination is the predominant driver of oncogenic rearrangement in ETV6-RUNX1 acute lymphoblastic leukemia. Nat Genet (2014) 2.72
Independent prognostic value of BCR-ABL1-like signature and IKZF1 deletion, but not high CRLF2 expression, in children with B-cell precursor ALL. Blood (2013) 2.34
MOSAIK: a hash-based algorithm for accurate next-generation sequencing short-read mapping. PLoS One (2014) 2.12
Integrative Clinical Sequencing in the Management of Refractory or Relapsed Cancer in Youth. JAMA (2015) 2.02
Genetic loss of SH2B3 in acute lymphoblastic leukemia. Blood (2013) 1.87
Targeting JAK1/2 and mTOR in murine xenograft models of Ph-like acute lymphoblastic leukemia. Blood (2012) 1.78
Recurrent DUX4 fusions in B cell acute lymphoblastic leukemia of adolescents and young adults. Nat Genet (2016) 1.71
Integrated genomic DNA/RNA profiling of hematologic malignancies in the clinical setting. Blood (2016) 1.66
Cancer genome-sequencing study design. Nat Rev Genet (2013) 1.55
Tyrosine kinome sequencing of pediatric acute lymphoblastic leukemia: a report from the Children's Oncology Group TARGET Project. Blood (2012) 1.47
The mutational landscape in pediatric acute lymphoblastic leukemia deciphered by whole genome sequencing. Hum Mutat (2015) 1.46
Inherited GATA3 variants are associated with Ph-like childhood acute lymphoblastic leukemia and risk of relapse. Nat Genet (2013) 1.45
Molecular genetics of B-precursor acute lymphoblastic leukemia. J Clin Invest (2012) 1.38
Successful tyrosine kinase inhibitor therapy in a refractory B-cell precursor acute lymphoblastic leukemia with EBF1-PDGFRB fusion. Haematologica (2013) 1.36
Function of Ikaros as a tumor suppressor in B cell acute lymphoblastic leukemia. Am J Blood Res (2013) 1.33
A 50-year journey to cure childhood acute lymphoblastic leukemia. Semin Hematol (2013) 1.32
Outcomes of children with BCR-ABL1–like acute lymphoblastic leukemia treated with risk-directed therapy based on the levels of minimal residual disease. J Clin Oncol (2014) 1.31
Children's Oncology Group's 2013 blueprint for research: acute lymphoblastic leukemia. Pediatr Blood Cancer (2012) 1.29
Sealer: a scalable gap-closing application for finishing draft genomes. BMC Bioinformatics (2015) 1.27
Efficacy of JAK/STAT pathway inhibition in murine xenograft models of early T-cell precursor (ETP) acute lymphoblastic leukemia. Blood (2015) 1.26
Childhood Acute Lymphoblastic Leukemia: Progress Through Collaboration. J Clin Oncol (2015) 1.26
Pax5 loss imposes a reversible differentiation block in B-progenitor acute lymphoblastic leukemia. Genes Dev (2014) 1.26
An intragenic ERG deletion is a marker of an oncogenic subtype of B-cell precursor acute lymphoblastic leukemia with a favorable outcome despite frequent IKZF1 deletions. Leukemia (2013) 1.22
Genomic characterization of childhood acute lymphoblastic leukemia. Semin Hematol (2013) 1.19
Redefining ALL classification: toward detecting high-risk ALL and implementing precision medicine. Blood (2015) 1.19
TET proteins and the control of cytosine demethylation in cancer. Genome Med (2015) 1.13
Activity of the Type II JAK2 Inhibitor CHZ868 in B Cell Acute Lymphoblastic Leukemia. Cancer Cell (2015) 1.10
Inherited genetic variation in childhood acute lymphoblastic leukemia. Blood (2015) 1.09
Transcription factor networks in B-cell differentiation link development to acute lymphoid leukemia. Blood (2015) 1.08
CONSERTING: integrating copy-number analysis with structural-variation detection. Nat Methods (2015) 1.08
A novel recurrent EP300-ZNF384 gene fusion in B-cell precursor acute lymphoblastic leukemia. Leukemia (2015) 1.07
Management of adult and paediatric acute lymphoblastic leukaemia in Asia: resource-stratified guidelines from the Asian Oncology Summit 2013. Lancet Oncol (2013) 1.07
Outlook on PI3K/AKT/mTOR inhibition in acute leukemia. Mol Cell Ther (2015) 1.05
A genome-wide association study of susceptibility to acute lymphoblastic leukemia in adolescents and young adults. Blood (2014) 1.04
Targeting the PI3K/mTOR Pathway in Pediatric Hematologic Malignancies. Front Oncol (2014) 1.03
Childhood B-acute lymphoblastic leukemia: a genetic update. Exp Hematol Oncol (2014) 1.01
Molecular pathways: molecular basis for sensitivity and resistance to JAK kinase inhibitors. Clin Cancer Res (2014) 0.99
Potent efficacy of combined PI3K/mTOR and JAK or ABL inhibition in murine xenograft models of Ph-like acute lymphoblastic leukemia. Blood (2016) 0.98
Biology of childhood acute lymphoblastic leukemia. Pediatr Clin North Am (2015) 0.97
Translating cancer genomes and transcriptomes for precision oncology. CA Cancer J Clin (2015) 0.97
Current concepts in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia. Front Oncol (2014) 0.97
Genomics of racial and ethnic disparities in childhood acute lymphoblastic leukemia. Cancer (2013) 0.96
Erk Negative Feedback Control Enables Pre-B Cell Transformation and Represents a Therapeutic Target in Acute Lymphoblastic Leukemia. Cancer Cell (2015) 0.96
Cancer susceptibility syndromes in children in the area of broad clinical use of massive parallel sequencing. Eur J Pediatr (2015) 0.95
12q24 locus association with type 1 diabetes: SH2B3 or ATXN2? World J Diabetes (2014) 0.95
Lessons from next-generation sequencing analysis in hematological malignancies. Blood Cancer J (2013) 0.94
The role of the Janus-faced transcription factor PAX5-JAK2 in acute lymphoblastic leukemia. Blood (2014) 0.94
Efficacy of Retinoids in IKZF1-Mutated BCR-ABL1 Acute Lymphoblastic Leukemia. Cancer Cell (2015) 0.93
Truncating Erythropoietin Receptor Rearrangements in Acute Lymphoblastic Leukemia. Cancer Cell (2016) 0.93
mTOR kinase inhibitors synergize with histone deacetylase inhibitors to kill B-cell acute lymphoblastic leukemia cells. Oncotarget (2015) 0.92
Comparative genomics reveals multistep pathogenesis of E2A-PBX1 acute lymphoblastic leukemia. J Clin Invest (2015) 0.92
Expression profiling of adult acute lymphoblastic leukemia identifies a BCR-ABL1-like subgroup characterized by high non-response and relapse rates. Haematologica (2015) 0.92
A health-care system perspective on implementing genomic medicine: pediatric acute lymphoblastic leukemia as a paradigm. Clin Pharmacol Ther (2013) 0.91
Combined targeting of JAK2 and Bcl-2/Bcl-xL to cure mutant JAK2-driven malignancies and overcome acquired resistance to JAK2 inhibitors. Cell Rep (2013) 0.91
Adult B-cell acute lymphoblastic leukemia cells display decreased PTEN activity and constitutive hyperactivation of PI3K/Akt pathway despite high PTEN protein levels. Haematologica (2014) 0.91
PAX5 is a tumor suppressor in mouse mutagenesis models of acute lymphoblastic leukemia. Blood (2015) 0.91
Diagnosis and subclassification of acute lymphoblastic leukemia. Mediterr J Hematol Infect Dis (2014) 0.88
New and emerging prognostic and predictive genetic biomarkers in B-cell precursor acute lymphoblastic leukemia. Haematologica (2016) 0.88
Identification of ETV6-RUNX1-like and DUX4-rearranged subtypes in paediatric B-cell precursor acute lymphoblastic leukaemia. Nat Commun (2016) 0.88
The pre-B-cell receptor checkpoint in acute lymphoblastic leukaemia. Leukemia (2015) 0.88
Genome-wide analysis links NFATC2 with asparaginase hypersensitivity. Blood (2015) 0.87
SH2B3 (LNK) mutations from myeloproliferative neoplasms patients have mild loss of function against wild type JAK2 and JAK2 V617F. Br J Haematol (2013) 0.87
Remaining challenges in childhood cancer and newer targeted therapeutics. Pediatr Clin North Am (2014) 0.87
Genomic Profiling of Adult and Pediatric B-cell Acute Lymphoblastic Leukemia. EBioMedicine (2016) 0.86
Nucleoporin genes in human diseases. Eur J Hum Genet (2016) 0.86
Rationale for targeting the pre-B-cell receptor signaling pathway in acute lymphoblastic leukemia. Blood (2015) 0.86
BCR-ABL1-like cases in pediatric acute lymphoblastic leukemia: a comparison between DCOG/Erasmus MC and COG/St. Jude signatures. Haematologica (2015) 0.86
Targeting mTOR for the treatment of B cell malignancies. Br J Clin Pharmacol (2016) 0.85
Biologic and clinical characteristics of adolescent and young adult cancers: Acute lymphoblastic leukemia, colorectal cancer, breast cancer, melanoma, and sarcoma. Cancer (2016) 0.85
A phase 1 dosing study of ruxolitinib in children with relapsed or refractory solid tumors, leukemias, or myeloproliferative neoplasms: A Children's Oncology Group phase 1 consortium study (ADVL1011). Pediatr Blood Cancer (2015) 0.85
NUP214-ABL1-mediated cell proliferation in T-cell acute lymphoblastic leukemia is dependent on the LCK kinase and various interacting proteins. Haematologica (2013) 0.85
Cross Cancer Genomic Investigation of Inflammation Pathway for Five Common Cancers: Lung, Ovary, Prostate, Breast, and Colorectal Cancer. J Natl Cancer Inst (2015) 0.85
DNA methylation-based subtype prediction for pediatric acute lymphoblastic leukemia. Clin Epigenetics (2015) 0.85
Emerging therapeutic paradigms to target the dysregulated Janus kinase/signal transducer and activator of transcription pathway in hematological malignancies. Leuk Lymphoma (2014) 0.84
Challenges and opportunities for international cooperative studies in pediatric hematopoeitic cell transplantation: priorities of the Westhafen Intercontinental Group. Biol Blood Marrow Transplant (2013) 0.84
Clonal conversion of B lymphoid leukemia reveals cross-lineage transfer of malignant states. Genes Dev (2016) 0.84
Thymic stromal lymphopoietin and cancer. J Immunol (2014) 0.84
Synergism of FAK and tyrosine kinase inhibition in Ph(+) B-ALL. JCI Insight (2016) 0.83
High Frequency and Poor Outcome of Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia in Adults. J Clin Oncol (2016) 0.83
Pre-BCR signaling in precursor B-cell acute lymphoblastic leukemia regulates PI3K/AKT, FOXO1 and MYC, and can be targeted by SYK inhibition. Leukemia (2016) 0.83
Integration of cytogenomic data for furthering the characterization of pediatric B-cell acute lymphoblastic leukemia: a multi-institution, multi-platform microarray study. Cancer Genet (2014) 0.82
Milestones in the curability of pediatric cancers. J Clin Oncol (2014) 0.81
Superenhancer reprogramming drives a B-cell-epithelial transition and high-risk leukemia. Genes Dev (2016) 0.81
Adults with Philadelphia chromosome-like acute lymphoblastic leukemia frequently have IGH-CRLF2 and JAK2 mutations, persistence of minimal residual disease and poor prognosis. Haematologica (2016) 0.81
JAK kinase targeting in hematologic malignancies: a sinuous pathway from identification of genetic alterations towards clinical indications. Haematologica (2015) 0.81
Genomic analyses identify recurrent MEF2D fusions in acute lymphoblastic leukaemia. Nat Commun (2016) 0.81
Evaluation of the in vitro and in vivo efficacy of the JAK inhibitor AZD1480 against JAK-mutated acute lymphoblastic leukemia. Mol Cancer Ther (2014) 0.80
Characterization of leukemias with ETV6-ABL1 fusion. Haematologica (2016) 0.80
SH2B3: a new leukemia predisposition gene. Blood (2013) 0.80
The clinical path to integrated genomics in ALL. Blood (2014) 0.80
Ph-like acute lymphoblastic leukemia: a high-risk subtype in adults. Blood (2016) 0.79
NUP214 fusion genes in acute leukemia (Review). Oncol Lett (2014) 0.79
The role of the RAS pathway in iAMP21-ALL. Leukemia (2016) 0.79
LNK (SH2B3): paradoxical effects in ovarian cancer. Oncogene (2014) 0.79
Relapse of BCR-ABL1-like ALL mediated by the ABL1 kinase domain mutation T315I following initial response to dasatinib treatment. Leukemia (2014) 0.79
Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol (2004) 101.91
Diagnosis of multiple cancer types by shrunken centroids of gene expression. Proc Natl Acad Sci U S A (2002) 30.32
Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution. Nature (2009) 18.08
Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia. Nature (2007) 17.68
Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin. Nat Genet (2010) 10.97
Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia. N Engl J Med (2009) 10.54
BCR-ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros. Nature (2008) 10.12
The genetic basis of early T-cell precursor acute lymphoblastic leukaemia. Nature (2012) 9.89
De novo assembly and analysis of RNA-seq data. Nat Methods (2010) 9.69
Acute lymphoblastic leukaemia. Lancet (2008) 8.54
Treating childhood acute lymphoblastic leukemia without cranial irradiation. N Engl J Med (2009) 7.95
CREST maps somatic structural variation in cancer genomes with base-pair resolution. Nat Methods (2011) 5.34
A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome-wide classification study. Lancet Oncol (2009) 5.22
JAK mutations in high-risk childhood acute lymphoblastic leukemia. Proc Natl Acad Sci U S A (2009) 4.98
deFuse: an algorithm for gene fusion discovery in tumor RNA-Seq data. PLoS Comput Biol (2011) 4.66
Fusion of PDGF receptor beta to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation. Cell (1994) 4.64
Rearrangement of CRLF2 in B-progenitor- and Down syndrome-associated acute lymphoblastic leukemia. Nat Genet (2009) 4.35
Improved early event-free survival with imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia: a children's oncology group study. J Clin Oncol (2009) 4.20
Single-cell profiling identifies aberrant STAT5 activation in myeloid malignancies with specific clinical and biologic correlates. Cancer Cell (2008) 4.06
Inhibition of FLT3 in MLL. Validation of a therapeutic target identified by gene expression based classification. Cancer Cell (2003) 3.75
Deregulated expression of cytokine receptor gene, CRLF2, is involved in lymphoid transformation in B-cell precursor acute lymphoblastic leukemia. Blood (2009) 3.50
Novel mutations in the inhibitory adaptor protein LNK drive JAK-STAT signaling in patients with myeloproliferative neoplasms. Blood (2010) 3.41
Key pathways are frequently mutated in high-risk childhood acute lymphoblastic leukemia: a report from the Children's Oncology Group. Blood (2011) 3.40
The diversity of BCR-ABL fusion proteins and their relationship to leukemia phenotype. Blood (1996) 3.39
Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta. N Engl J Med (2002) 3.08
Arf gene loss enhances oncogenicity and limits imatinib response in mouse models of Bcr-Abl-induced acute lymphoblastic leukemia. Proc Natl Acad Sci U S A (2006) 3.04
Fusion of NUP214 to ABL1 on amplified episomes in T-cell acute lymphoblastic leukemia. Nat Genet (2004) 2.96
High-resolution genomic profiling of childhood ALL reveals novel recurrent genetic lesions affecting pathways involved in lymphocyte differentiation and cell cycle progression. Leukemia (2007) 2.85
Flt3 mutations from patients with acute myeloid leukemia induce transformation of 32D cells mediated by the Ras and STAT5 pathways. Blood (2000) 2.70
Activating FLT3 mutations in CD117/KIT(+) T-cell acute lymphoblastic leukemias. Blood (2004) 2.60
Gain-of-function mutations in interleukin-7 receptor-α (IL7R) in childhood acute lymphoblastic leukemias. J Exp Med (2011) 2.59
Functional screening identifies CRLF2 in precursor B-cell acute lymphoblastic leukemia. Proc Natl Acad Sci U S A (2009) 2.54
The Pediatric Cancer Genome Project. Nat Genet (2012) 2.49
Oncogenic IL7R gain-of-function mutations in childhood T-cell acute lymphoblastic leukemia. Nat Genet (2011) 2.32
The mTOR inhibitor CCI-779 induces apoptosis and inhibits growth in preclinical models of primary adult human ALL. Blood (2005) 2.25
Lnk inhibits erythropoiesis and Epo-dependent JAK2 activation and downstream signaling pathways. Blood (2005) 2.17
IKZF1 (Ikaros) deletions in BCR-ABL1-positive acute lymphoblastic leukemia are associated with short disease-free survival and high rate of cumulative incidence of relapse: a GIMEMA AL WP report. J Clin Oncol (2009) 2.00
The TEL/platelet-derived growth factor beta receptor (PDGF beta R) fusion in chronic myelomonocytic leukemia is a transforming protein that self-associates and activates PDGF beta R kinase-dependent signaling pathways. Proc Natl Acad Sci U S A (1996) 1.98
Nup358/RanBP2 attaches to the nuclear pore complex via association with Nup88 and Nup214/CAN and plays a supporting role in CRM1-mediated nuclear protein export. Mol Cell Biol (2004) 1.70
Aberrant STAT5 and PI3K/mTOR pathway signaling occurs in human CRLF2-rearranged B-precursor acute lymphoblastic leukemia. Blood (2012) 1.66
LNK mutation studies in blast-phase myeloproliferative neoplasms, and in chronic-phase disease with TET2, IDH, JAK2 or MPL mutations. Leukemia (2010) 1.64
Bambino: a variant detector and alignment viewer for next-generation sequencing data in the SAM/BAM format. Bioinformatics (2011) 1.61
ABL1 fusion genes in hematological malignancies: a review. Eur J Haematol (2011) 1.61
EBF contains a novel zinc coordination motif and multiple dimerization and transcriptional activation domains. EMBO J (1995) 1.57
Incidence and diversity of PAX5 fusion genes in childhood acute lymphoblastic leukemia. Leukemia (2008) 1.48
A BCR-JAK2 fusion gene as the result of a t(9;22)(p24;q11.2) translocation in a patient with a clinically typical chronic myeloid leukemia. Genes Chromosomes Cancer (2005) 1.34
Activating mutation in the TSLPR gene in B-cell precursor lymphoblastic leukemia. Leukemia (2009) 1.33
Augmented therapy improves outcome for pediatric high risk acute lymphocytic leukemia: results of Children's Oncology Group trial P9906. Pediatr Blood Cancer (2011) 1.33
Transcription factors drive B cell development. Curr Opin Immunol (2006) 1.28
Rapid complete cytogenetic remission after upfront dasatinib monotherapy in a patient with a NUP214-ABL1-positive T-cell acute lymphoblastic leukemia. Leukemia (2008) 1.10
Fibroblast growth factor receptor and platelet-derived growth factor receptor abnormalities in eosinophilic myeloproliferative disorders. Acta Haematol (2008) 1.10
A novel translocation, t(14;19)(q32;p13), involving IGH@ and the cytokine receptor for erythropoietin. Leukemia (2008) 1.08
ALK fusion genes in children with atypical myeloproliferative leukemia. Leukemia (2010) 1.05
Activity of tyrosine kinase inhibitors against human NUP214-ABL1-positive T cell malignancies. Leukemia (2008) 0.99
A BCR-JAK2 fusion gene as the result of a t(9;22)(p24;q11) in a patient with acute myeloid leukemia. Cancer Genet Cytogenet (2008) 0.99
Kinase activation and transformation by NUP214-ABL1 is dependent on the context of the nuclear pore. Mol Cell (2008) 0.98
MicroRNA expression profiles classify human cancers. Nature (2005) 69.12
Genome-wide profiles of STAT1 DNA association using chromatin immunoprecipitation and massively parallel sequencing. Nat Methods (2007) 45.04
Circos: an information aesthetic for comparative genomics. Genome Res (2009) 40.02
The landscape of somatic copy-number alteration across human cancers. Nature (2010) 31.88
Genome-wide association study identifies novel breast cancer susceptibility loci. Nature (2007) 29.23
Genome sequence of the Brown Norway rat yields insights into mammalian evolution. Nature (2004) 24.40
A genome-wide association study identifies alleles in FGFR2 associated with risk of sporadic postmenopausal breast cancer. Nat Genet (2007) 22.96
Genome-wide association study of prostate cancer identifies a second risk locus at 8q24. Nat Genet (2007) 21.18
Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences. Proc Natl Acad Sci U S A (2002) 20.48
International network of cancer genome projects. Nature (2010) 20.35
Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy (2012) 20.08
Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med (2013) 19.87
Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution. Nature (2009) 18.08
Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia. Nature (2007) 17.68
Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol (2003) 17.67
Multiple loci identified in a genome-wide association study of prostate cancer. Nat Genet (2008) 17.65
Transcriptional maps of 10 human chromosomes at 5-nucleotide resolution. Science (2005) 16.82
The Genome sequence of the SARS-associated coronavirus. Science (2003) 16.68
Evolutionary and biomedical insights from the rhesus macaque genome. Science (2007) 16.21
Replicating genotype-phenotype associations. Nature (2007) 16.11
Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell (2010) 15.20
The NIH Roadmap Epigenomics Mapping Consortium. Nat Biotechnol (2010) 13.99
Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med (2006) 13.54
The genome sequence of Caenorhabditis briggsae: a platform for comparative genomics. PLoS Biol (2003) 13.32
The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. Cancer Cell (2010) 13.13
ARID1A mutations in endometriosis-associated ovarian carcinomas. N Engl J Med (2010) 13.07
T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med (2011) 12.58
The clonal and mutational evolution spectrum of primary triple-negative breast cancers. Nature (2012) 11.91
Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling. Cancer Cell (2002) 11.83
The genome of the African trypanosome Trypanosoma brucei. Science (2005) 11.48
Treatment of acute lymphoblastic leukemia. N Engl J Med (2006) 11.30
Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin. Nat Genet (2010) 10.97
Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia. N Engl J Med (2009) 10.54
Cyclic GMP-AMP synthase is a cytosolic DNA sensor that activates the type I interferon pathway. Science (2012) 10.47
Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. N Engl J Med (2012) 10.20
Application of massively parallel sequencing to microRNA profiling and discovery in human embryonic stem cells. Genome Res (2008) 10.18
BCR-ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros. Nature (2008) 10.12
Profiling the HeLa S3 transcriptome using randomly primed cDNA and massively parallel short-read sequencing. Biotechniques (2008) 10.02
Clinical effect of point mutations in myelodysplastic syndromes. N Engl J Med (2011) 9.90
The genetic basis of early T-cell precursor acute lymphoblastic leukaemia. Nature (2012) 9.89